IMARC Group, a leading market research company, has recently releases report titled “Cancer Cachexia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global cancer cachexia market growth, share, size, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How big is the cancer cachexia market?
The global cancer cachexia market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2023-2028.
What is Cancer Cachexia?
Cancer cachexia is a complex and multifactorial syndrome characterized by the loss of skeletal muscle mass, asthenia, negative protein balance, loss of appetite, and anemia. It shows symptoms of decreased secretion of host anabolic hormones and abnormalities in protein, lipid, and carbohydrate metabolism. It is divided into three stages, which include pre-cachexia, cachexia, and refractory cachexia. It generally occurs in patients with pancreatic and lung cancer, tuberculosis (TB), chronic renal failure, obstructive pulmonary disease (COPD), and human immunodeficiency virus (HIV). It can be treated with combination therapy and various approaches, including diet modification, nutritional supplements, adapted exercise, and medications that decrease inflammation.
Request Free Sample Copy of This Report: https://www.imarcgroup.com/cancer-cachexia-market/requestsample
What are the growth prospects and trends in the cancer cachexia industry?
At present, the rising prevalence of liver, lung, pancreatic, and other cancers, along with the increasing aging population, is catalyzing the demand for medications and therapies to prevent cancer cachexia.
In addition, the growing awareness among the masses about the benefits of early diagnosis and the availability of novel therapeutic drugs to prevent the severity of cancer is positively influencing the market. Apart from this, the introduction of numerous nutritional and appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, is creating a positive market outlook.
Moreover, the increasing number of hospitals and healthcare centers, coupled with significant technological advancements in the healthcare industry, is propelling the growth of the market.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Therapeutics:
• Progestogens
• Corticosteroids
• Combination Therapy
• Others
Breakup by Mode of Action:
• Appetite Stimulators
• Weight Loss Stabilizers
Breakup by Distribution Channel:
• Hospital Stores
• Retail Pharmacy
• Online Pharmacy
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE Co. KGaA), Helsinn Healthcare SA, Merck Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/